2,561 reports of this reaction
1.6% of all METOCLOPRAMIDE reports
#13 most reported adverse reaction
DYSKINESIA is the #13 most commonly reported adverse reaction for METOCLOPRAMIDE, manufactured by ANI Pharmaceuticals, Inc.. There are 2,561 FDA adverse event reports linking METOCLOPRAMIDE to DYSKINESIA. This represents approximately 1.6% of all 156,854 adverse event reports for this drug.
Patients taking METOCLOPRAMIDE who experience dyskinesia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSKINESIA is a less commonly reported adverse event for METOCLOPRAMIDE, but still significant enough to appear in the safety profile.
In addition to dyskinesia, the following adverse reactions have been reported for METOCLOPRAMIDE:
The following drugs have also been linked to dyskinesia in FDA adverse event reports:
DYSKINESIA has been reported as an adverse event in 2,561 FDA reports for METOCLOPRAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSKINESIA accounts for approximately 1.6% of all adverse event reports for METOCLOPRAMIDE, making it a notable side effect.
If you experience dyskinesia while taking METOCLOPRAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.